Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden

Adults with relapsed/refractory acute lymphoblastic leukemia (R/R ALL) have a poor prognosis, especially if disease burden is high. This post hoc analysis of the phase 3 INO-VATE trial examined the efficacy and safety of inotuzumab ozogamicin (InO) vs. standard of care chemotherapy (SC) among R/R AL...

Descripción completa

Detalles Bibliográficos
Autores principales: DeAngelo, Daniel J., Advani, Anjali S., Marks, David I., Stelljes, Matthias, Liedtke, Michaela, Stock, Wendy, Gökbuget, Nicola, Jabbour, Elias, Merchant, Akil, Wang, Tao, Vandendries, Erik, Neuhof, Alexander, Kantarjian, Hagop, O’Brien, Susan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7414105/
https://www.ncbi.nlm.nih.gov/pubmed/32769965
http://dx.doi.org/10.1038/s41408-020-00345-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7414105/
https://www.ncbi.nlm.nih.gov/pubmed/32769965
http://dx.doi.org/10.1038/s41408-020-00345-8

Ejemplares similares